Valeant Pharma (VRX) Misses Q2 EPS by 10c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Valeant Pharmaceuticals (VRX) PT to $285 at BMO Capital Following 'Strong and Clean' Quarter
July 24, 2015 7:45 AM EDTBMO Capital analyst Alex Arfaei reiterated an Outperform rating and boosted his price target on Valeant Pharmaceuticals (NYSE: VRX) to $285.00 (from $266.00) following a 'strong and clean quarter.'
Arfaei commented, "quarter. The legacy Valeant business in the US continues to exceed our expectations, driven by the US dermatology and Bausch + Lomb (B+L) businesses, including new product... More
